Shopping Cart
Remove All
Your shopping cart is currently empty
Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 200 mg | $50 | In Stock | In Stock | |
| 500 mg | $97 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
| Description | Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. |
| Targets&IC50 | CRL4CRBN:250 nM (Kd) |
| In vitro | Thalidomide selectively inhibits the production of tumor necrosis factor-alpha (TNF-α) in human monocytes stimulated by lipopolysaccharides and other agonists. Its suppression of TNF-α is mediated through the enhancement of mRNA degradation. Moreover, thalidomide exerts a direct effect on MM cell lines by inducing apoptosis and G1 phase growth arrest, as well as on patient MM cells resistant to melphalan, doxorubicin hydrochloride, and dexamethasone. |
| In vivo | Administering 200mg/kg of Thalidomide resulted in the inhibition of vascularization in the corneal region within rabbits, with the inhibition rate ranging from 30% to 51% across three experiments. |
| Synonyms | Thalomid, Sedoval |
| Molecular Weight | 258.23 |
| Formula | C13H10N2O4 |
| Cas No. | 50-35-1 |
| Smiles | O=C1N(C2CCC(=O)NC2=O)C(=O)c2ccccc12 |
| Relative Density. | 1.2944 g/cm3 (Estimated) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 6.5 mg/mL (25.17 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.87 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.